Tao Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tao Huang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Kristine E. Konopka
Department of Pathology, University of Michigan, Ann Arbor, MI
3 shared publications - David B. Chapel
Department of Pathology, University of Michigan, Ann Arbor, MI
2 shared publications Jeffrey L. Myers
Departments of Pathology (D.R.F.E., S.M.H., R.W.L., J.L.M., T.H.)
2 shared publicationsLiron Pantanowitz
University of Pittsburgh Medical Center
2 shared publications- Xin Jing
Department of Pathology, University of Michigan, Ann Arbor, Michigan
2 shared publications - Abtin Riasatian
Kimia Lab(3), University of Waterloo, Waterloo, Canada
1 shared publication
Latest Publications
- 28 July 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (10) , 1252-1261
Metastatic High-Grade Endometrioid Carcinoma to the Lung With Pilomatrix Carcinoma-Like Morphology
Pilomatrix-like high-grade endometrioid carcinoma (PiMHEC) is a recently described aggressive variant of endometrioid carcinoma characterized by solid nests of basaloid cells with abrupt keratinization, geographic necrosis, and anucleated ghost cells. PiMHEC shows aberrant nuclear and cytoplasmic β-catenin staining, loss of PAX8 and hormone receptor expression, and aberrant expression of CDX2 and neuroendocrine markers. As a result, when presenting as metastatic disease, particularly in the lung, PiMHEC can be misdiagnosed as primary pulmonary non–small cell carcinoma or metastatic carcinoma of nongynecologic origin. We identified 7 cases of metastatic PiMHEC to the lung through our institution’s thoracic consultation service. None, including those with a known history, were initially diagnosed with metastatic endometrial carcinoma. All cases demonstrated aberrant β-catenin staining and loss of PAX8, ER, and PR. Radiographically, all cases presented with multiple to innumerable bilateral lung masses. In conclusion, in female patients presenting with multiple lung masses, morphologic features resembling pilomatrix carcinoma, and aberrant β-catenin staining, metastatic PiMHEC should remain high on differential diagnosis even without Mullerian marker immunoreactivity or a history of Mullerian malignancy. Our case series further confirms the aggressive nature of PiMHEC: 3 patients developed lung metastases within 3 months of their initial diagnosis of endometrial carcinoma, 2 presented with postmenopausal bleeding or endometrial thickening and simultaneous lung metastases, and in 1 case, a lung biopsy led to endometrial sampling without clinical suspicion of endometrial carcinoma. Recognizing the morphologic and immunophenotypic features of pulmonary metastases of PiMHEC is crucial to avoid misdiagnosis.
- 28 July 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (10) , 1252-1261
Metastatic High-Grade Endometrioid Carcinoma to the Lung With Pilomatrix Carcinoma-Like Morphology
Pilomatrix-like high-grade endometrioid carcinoma (PiMHEC) is a recently described aggressive variant of endometrioid carcinoma characterized by solid nests of basaloid cells with abrupt keratinization, geographic necrosis, and anucleated ghost cells. PiMHEC shows aberrant nuclear and cytoplasmic β-catenin staining, loss of PAX8 and hormone receptor expression, and aberrant expression of CDX2 and neuroendocrine markers. As a result, when presenting as metastatic disease, particularly in the lung, PiMHEC can be misdiagnosed as primary pulmonary non–small cell carcinoma or metastatic carcinoma of nongynecologic origin. We identified 7 cases of metastatic PiMHEC to the lung through our institution’s thoracic consultation service. None, including those with a known history, were initially diagnosed with metastatic endometrial carcinoma. All cases demonstrated aberrant β-catenin staining and loss of PAX8, ER, and PR. Radiographically, all cases presented with multiple to innumerable bilateral lung masses. In conclusion, in female patients presenting with multiple lung masses, morphologic features resembling pilomatrix carcinoma, and aberrant β-catenin staining, metastatic PiMHEC should remain high on differential diagnosis even without Mullerian marker immunoreactivity or a history of Mullerian malignancy. Our case series further confirms the aggressive nature of PiMHEC: 3 patients developed lung metastases within 3 months of their initial diagnosis of endometrial carcinoma, 2 presented with postmenopausal bleeding or endometrial thickening and simultaneous lung metastases, and in 1 case, a lung biopsy led to endometrial sampling without clinical suspicion of endometrial carcinoma. Recognizing the morphologic and immunophenotypic features of pulmonary metastases of PiMHEC is crucial to avoid misdiagnosis.
- Open Access
- 21 July 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 533-537
Immunohistochemical characterization of peritoneal inclusion cysts with squamous metaplasia
Aims: Peritoneal inclusion cysts (PICs) are mesothelial‐lined cysts that can uncommonly develop squamous metaplasia. Here, we describe the immunophenotype of PICs with squamous metaplasia using a comprehensive immunohistochemical (IHC) panel. Methods and results: We collected surgical excisions of PICs with squamous metaplasia from our institution and cases sent to our extramural consultation service. An IHC panel was used to characterize the immunophenotype, which included antibodies to claudin 4, WT‐1, D2‐40, calretinin, CK5/6, p40/p63, PAX8, BAP1, MTAP and merlin. 10 cases of PICs with squamous metaplasia were identified. The average age was 51 years, with 8 females and 2 males. On histology, all PICs ( n = 10) showed diffuse squamous metaplasia. The cyst lining cells exhibited a squamous epithelial phenotype with diffuse expression of claudin 4 and p63/p40 in the suprabasal cells that also showed consistent co‐expression of WT1 in all cases. In contrast, the basal layer displayed a mesothelial phenotype, demonstrating immunoreactivity to WT1 and D2‐40 and lacking expression of claudin 4. Calretinin showed complete loss of expression in both the basal and parabasal cells. All cases showed retained expression of BAP1, MTAP and merlin. Conclusions: PICs with squamous metaplasia express a unique mixed epithelial and mesothelial immunophenotype. The basal layer shows an immunophenotype consistent with mesothelial cells, and the suprabasal layers show an immunophenotype consistent with epithelial/squamous cells. Knowing the detailed immunophenotype of PIC with squamous metaplasia is helpful for correctly recognizing this lesion.
- 21 July 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 533-537
Open AccessImmunohistochemical characterization of peritoneal inclusion cysts with squamous metaplasia
Aims: Peritoneal inclusion cysts (PICs) are mesothelial‐lined cysts that can uncommonly develop squamous metaplasia. Here, we describe the immunophenotype of PICs with squamous metaplasia using a comprehensive immunohistochemical (IHC) panel. Methods and results: We collected surgical excisions of PICs with squamous metaplasia from our institution and cases sent to our extramural consultation service. An IHC panel was used to characterize the immunophenotype, which included antibodies to claudin 4, WT‐1, D2‐40, calretinin, CK5/6, p40/p63, PAX8, BAP1, MTAP and merlin. 10 cases of PICs with squamous metaplasia were identified. The average age was 51 years, with 8 females and 2 males. On histology, all PICs ( n = 10) showed diffuse squamous metaplasia. The cyst lining cells exhibited a squamous epithelial phenotype with diffuse expression of claudin 4 and p63/p40 in the suprabasal cells that also showed consistent co‐expression of WT1 in all cases. In contrast, the basal layer displayed a mesothelial phenotype, demonstrating immunoreactivity to WT1 and D2‐40 and lacking expression of claudin 4. Calretinin showed complete loss of expression in both the basal and parabasal cells. All cases showed retained expression of BAP1, MTAP and merlin. Conclusions: PICs with squamous metaplasia express a unique mixed epithelial and mesothelial immunophenotype. The basal layer shows an immunophenotype consistent with mesothelial cells, and the suprabasal layers show an immunophenotype consistent with epithelial/squamous cells. Knowing the detailed immunophenotype of PIC with squamous metaplasia is helpful for correctly recognizing this lesion.
- 9 May 2025
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 45 (3) , 235-240
A Case Report of Uterine Dedifferentiated Mesonephric-Like Adenocarcinoma With Comprehensive Molecular Profiling
Mesonephric-like adenocarcinoma (MLA) of the uterus is a rare, aggressive malignancy of presumed Müllerian origin that was recently included in the 2020 World Health Organization (WHO) Classification of Female Genital Tumours. MLA is challenging to diagnose given its rarity and morphologic heterogeneity. The recently published first case report of MLA that underwent dedifferentiation via TP53 mutation expands the morphologic spectrum of dedifferentiated carcinoma. In here, we describe a second case of an endometrial MLA with dedifferentiation from a 41-yr-old woman who presented with bilateral ovarian masses, peritoneal carcinomatosis, and hypercalcemia. A diagnosis of small cell carcinoma of the ovary, hypercalcemic type, was initially rendered at an outside institution from an omental biopsy, which only showed the undifferentiated component. The subsequent endometrial curettings performed at our institution showed both the MLA and undifferentiated components, each of which demonstrated distinct immunophenotype with the immunoreactivity to epithelial markers, GATA3 and TTF1 limited to the MLA component and the aberrant nuclear expression of beta catenin, global loss of expression of SMARCA4 and loss of expression of SMARCA2 limited to the undifferentiated component. Molecular studies on the undifferentiated component from the omental biopsy identified not only a mutation in KRAS , gene mutation commonly seen in MLA, but also mutations in SMARCA4 and CTNNB1 . In summary, we describe a second case of dedifferentiated MLA with dedifferentiation driven by various genetic alterations, including SMARCA4 and CTNNB1 gene mutations, novel gene alterations that have never been described in dedifferentiated MLA.
- 9 May 2025
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 45 (3) , 235-240
A Case Report of Uterine Dedifferentiated Mesonephric-Like Adenocarcinoma With Comprehensive Molecular Profiling
Mesonephric-like adenocarcinoma (MLA) of the uterus is a rare, aggressive malignancy of presumed Müllerian origin that was recently included in the 2020 World Health Organization (WHO) Classification of Female Genital Tumours. MLA is challenging to diagnose given its rarity and morphologic heterogeneity. The recently published first case report of MLA that underwent dedifferentiation via TP53 mutation expands the morphologic spectrum of dedifferentiated carcinoma. In here, we describe a second case of an endometrial MLA with dedifferentiation from a 41-yr-old woman who presented with bilateral ovarian masses, peritoneal carcinomatosis, and hypercalcemia. A diagnosis of small cell carcinoma of the ovary, hypercalcemic type, was initially rendered at an outside institution from an omental biopsy, which only showed the undifferentiated component. The subsequent endometrial curettings performed at our institution showed both the MLA and undifferentiated components, each of which demonstrated distinct immunophenotype with the immunoreactivity to epithelial markers, GATA3 and TTF1 limited to the MLA component and the aberrant nuclear expression of beta catenin, global loss of expression of SMARCA4 and loss of expression of SMARCA2 limited to the undifferentiated component. Molecular studies on the undifferentiated component from the omental biopsy identified not only a mutation in KRAS , gene mutation commonly seen in MLA, but also mutations in SMARCA4 and CTNNB1 . In summary, we describe a second case of dedifferentiated MLA with dedifferentiation driven by various genetic alterations, including SMARCA4 and CTNNB1 gene mutations, novel gene alterations that have never been described in dedifferentiated MLA.
- 1 October 2024
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (3) , 636-645
Aberrant CD45 Immunoreactivity in Neuroendocrine Neoplasms: A Diagnostic Pitfall—Report of 10 Specimens and Clinical Recommendations
Leukocyte common antigen (LCA), or CD45, is classically thought of as a leukocyte-exclusive protein, and as such, CD45 immunohistochemistry (IHC) is often used as a key differentiator between non-Hodgkin lymphomas (NHLs) and morphologically similar neuroendocrine neoplasms (NENs). Herein, we report our experience regarding aberrant CD45 immunoreactivity in a series of NENs. A natural language search was used to retrieve desired archival patient files. All prior NENs which had a positive neuroendocrine diagnosis or IHC results (synaptophysin, chromogranin, CD56, and/or neuron-specific enolase), as well as CD45 staining performed, were reviewed for possible CD45 positivity ( n = 686). Among these 686 NENs, 10 were aberrantly positive for CD45 staining. CD45 showed nuclear, cytoplasmic, and/or membranous staining in tumor cells. The significance of such staining is unclear. Albeit for a minority of patients, pathologists should be aware that NENs may aberrantly stain with CD45 and thereby pose a diagnostic pitfall. Therefore, broadening routine IHC panels is recommended to differentiate NENs more clearly from NHLs.
- 1 October 2024
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (3) , 636-645
Aberrant CD45 Immunoreactivity in Neuroendocrine Neoplasms: A Diagnostic Pitfall—Report of 10 Specimens and Clinical Recommendations
Leukocyte common antigen (LCA), or CD45, is classically thought of as a leukocyte-exclusive protein, and as such, CD45 immunohistochemistry (IHC) is often used as a key differentiator between non-Hodgkin lymphomas (NHLs) and morphologically similar neuroendocrine neoplasms (NENs). Herein, we report our experience regarding aberrant CD45 immunoreactivity in a series of NENs. A natural language search was used to retrieve desired archival patient files. All prior NENs which had a positive neuroendocrine diagnosis or IHC results (synaptophysin, chromogranin, CD56, and/or neuron-specific enolase), as well as CD45 staining performed, were reviewed for possible CD45 positivity ( n = 686). Among these 686 NENs, 10 were aberrantly positive for CD45 staining. CD45 showed nuclear, cytoplasmic, and/or membranous staining in tumor cells. The significance of such staining is unclear. Albeit for a minority of patients, pathologists should be aware that NENs may aberrantly stain with CD45 and thereby pose a diagnostic pitfall. Therefore, broadening routine IHC panels is recommended to differentiate NENs more clearly from NHLs.
- 31 May 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (3) , 322-330
Clinically Occult Diffuse Pleural Mesothelioma in Patients Presenting With Spontaneous Pneumothorax
Objectives: To report histologic features of unsuspected diffuse pleural mesothelioma (DPM) in surgical specimens for pneumothorax and demonstrate how ancillary markers support a diagnosis of malignancy in this context. We explored whether pneumothorax may be a clinical manifestation of mesothelioma in situ (MIS). Methods: A single-institution database search identified patients who underwent surgical resection for spontaneous pneumothorax (n = 229) and/or were diagnosed with DPM (n = 88) from 2000 to 2020. Results: Spontaneous pneumothorax without clinical, radiologic, or intraoperative suspicion of mesothelioma was the initial presentation in 2 (2.3%) of 88 patients diagnosed with DPM. This represented 0.9% (2/229) of all patients undergoing surgical management of pneumothorax but accounted for a larger proportion of older patients (12.5% older than 70 years). Immunohistochemistry for BAP-1 and/or MTAP confirmed the diagnosis of DPM in 2 cases. Mesothelioma in situ was identified retrospectively by immunohistochemistry in 1 case of spontaneous pneumothorax from a 77-year-old man who developed invasive DPM 25 months later. No additional cases of MIS were identified in 19 surgical lung resections for spontaneous pneumothorax. Conclusions: Histologic examination of bleb resections with ancillary testing for cases with ambiguous features is essential for detection of early DPM. It is uncertain whether spontaneous pneumothorax may represent a clinical manifestation of MIS.
- 31 May 2023
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 160 (3) , 322-330
Clinically Occult Diffuse Pleural Mesothelioma in Patients Presenting With Spontaneous Pneumothorax
Objectives: To report histologic features of unsuspected diffuse pleural mesothelioma (DPM) in surgical specimens for pneumothorax and demonstrate how ancillary markers support a diagnosis of malignancy in this context. We explored whether pneumothorax may be a clinical manifestation of mesothelioma in situ (MIS). Methods: A single-institution database search identified patients who underwent surgical resection for spontaneous pneumothorax (n = 229) and/or were diagnosed with DPM (n = 88) from 2000 to 2020. Results: Spontaneous pneumothorax without clinical, radiologic, or intraoperative suspicion of mesothelioma was the initial presentation in 2 (2.3%) of 88 patients diagnosed with DPM. This represented 0.9% (2/229) of all patients undergoing surgical management of pneumothorax but accounted for a larger proportion of older patients (12.5% older than 70 years). Immunohistochemistry for BAP-1 and/or MTAP confirmed the diagnosis of DPM in 2 cases. Mesothelioma in situ was identified retrospectively by immunohistochemistry in 1 case of spontaneous pneumothorax from a 77-year-old man who developed invasive DPM 25 months later. No additional cases of MIS were identified in 19 surgical lung resections for spontaneous pneumothorax. Conclusions: Histologic examination of bleb resections with ancillary testing for cases with ambiguous features is essential for detection of early DPM. It is uncertain whether spontaneous pneumothorax may represent a clinical manifestation of MIS.
- 1 January 2022
- Published by Springer Nature
- p. 15-23
Respiratory System
- 1 January 2022
- Published by Springer Nature
- p. 51-66
Endocrine Glands
- Open Access
- 1 December 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (12) , 2172-2183
Selection, Visualization, and Interpretation of Deep Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
- 1 December 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (12) , 2172-2183
Open AccessSelection, Visualization, and Interpretation of Deep Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
- 29 October 2021
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 41 (5) , 535-540
Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report
Mesothelioma in situ has been proposed as a precursor to malignant mesothelioma arising in the pleura or peritoneum. We report a case of malignant peritoneal mesothelioma which progressed from mesothelioma in situ over a 10-mo period in a 24-yr-old woman with stage IV endometriosis. Initial surgery showed deeply infiltrative endometriosis with progestin effect. Postoperatively the patient had intractable pelvic pain and vaginal discharge. Imaging studies were negative. Repeat laparoscopy 10 mo later revealed vesicular lesions on the omentum and pinpoint white lesions studding the small bowel, appendix, and pelvic peritoneum. A diagnosis of epithelioid mesothelioma was established on biopsy of the omentum and confirmed by immunohistochemistry showing complete loss of BRCA1-associated protein-1 (BAP1) nuclear staining. Retrospectively, BAP1 loss was identified in the cytologically bland, single-layer surface mesothelium of the prior resection specimen, consistent with mesothelioma in situ. The patient underwent genetic testing and was found to have a pathogenic germline mutation in BAP1.
- 29 October 2021
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 41 (5) , 535-540
Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report
Mesothelioma in situ has been proposed as a precursor to malignant mesothelioma arising in the pleura or peritoneum. We report a case of malignant peritoneal mesothelioma which progressed from mesothelioma in situ over a 10-mo period in a 24-yr-old woman with stage IV endometriosis. Initial surgery showed deeply infiltrative endometriosis with progestin effect. Postoperatively the patient had intractable pelvic pain and vaginal discharge. Imaging studies were negative. Repeat laparoscopy 10 mo later revealed vesicular lesions on the omentum and pinpoint white lesions studding the small bowel, appendix, and pelvic peritoneum. A diagnosis of epithelioid mesothelioma was established on biopsy of the omentum and confirmed by immunohistochemistry showing complete loss of BRCA1-associated protein-1 (BAP1) nuclear staining. Retrospectively, BAP1 loss was identified in the cytologically bland, single-layer surface mesothelium of the prior resection specimen, consistent with mesothelioma in situ. The patient underwent genetic testing and was found to have a pathogenic germline mutation in BAP1.
- 1 July 2020
- Published by Wolters Kluwer Health in AJSP: Reviews and Reports
- Vol. 25 (4) , 156-160
Go Gross or Go Home: The Importance of Gross Examination in Lung Cancer Staging and Diagnosis of Nonneoplastic Diseases
Gross examination is fundamental to the practice of surgical pathology. Accurate diagnosis can often be made based on the classic gross appearance of a lung lesion. On the other hand, inaccurate diagnosis or wrong tumor staging is unavoidable if lesions are missed, unrecognized, or inadequately sampled. Different grossing techniques should be used for grossing neoplastic and nonneoplastic lung specimens.
- 1 July 2020
- Published by Wolters Kluwer Health in AJSP: Reviews and Reports
- Vol. 25 (4) , 156-160
Go Gross or Go Home: The Importance of Gross Examination in Lung Cancer Staging and Diagnosis of Nonneoplastic Diseases
Gross examination is fundamental to the practice of surgical pathology. Accurate diagnosis can often be made based on the classic gross appearance of a lung lesion. On the other hand, inaccurate diagnosis or wrong tumor staging is unavoidable if lesions are missed, unrecognized, or inadequately sampled. Different grossing techniques should be used for grossing neoplastic and nonneoplastic lung specimens.